Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new study on relative rates of survival at 10 years, just published on line, is probably going to get differing reactions from patients and from physicians depending on their individual points of view.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: comparative, mortality, outcome, survival | 7 Comments »
No one seems to be quite sure what to make of this, but a new study has suggested that men who are diagnosed with clinically detectable prostate cancer — but do not actually die from their prostate cancer — are at higher risk for all other cause mortality than men who show no signs or symptoms of [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: all other cause, mortality, non-prostate-cancer | 5 Comments »
A new article published on line late Friday in the Journal of the National Cancer Institute shows “no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening” for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: mortality, risk, screening, testing | 11 Comments »
A new analysis of information from the Surveillance, Epidemiology and End Results (SEER) database suggests that the “hazard” for prostate cancer-specific mortality after radical prostatectomy is very low but that it does increase in a continuous manner for at least 15 years post-treatment.
Filed under: Living with Prostate Cancer, Management | Tagged: hazard, mortality, PCSM, prostate cancer-specific, radical prostatectomy, surgery | 6 Comments »
An article by Markert et al., just published on line in the Proceedings of the National Academy of Sciences, suggests that microarray analysis of messenger ribonucleic acid (mRNA) expression in prostate cancer tumors may be an independent indicator of the aggressiveness of prostate cancers in individual patients.
Filed under: Diagnosis, Management, Risk | Tagged: expression. signature, gene, mortality, outcome, profile, risk | 1 Comment »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
The October issue of the Canadian Journal of Urology contains an interesting and thorough review of the available data on the value of screening for prostate cancer as seen by a group including urologists, urologic oncologists, medical oncologists, radiation oncologists, and a highly regarded primary care physician.
Filed under: Diagnosis, Risk | Tagged: mortality, PSA, risk, screening, testing | Leave a Comment »
The debate over the merits and risks of widespread screening for prostate cancer using the PSA test is hardly confined to the USA. A new article (in German) in the journal Urologie A addresses exactly the same issues as have recently received so much attention here in the States.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mortality, PSA, risk, screening | 1 Comment »
A population-based analysis of mortality data for men diagnosed with prostate cancer from three European nations suggests that “a small but important group of older patients” initially present with late stage prostate cancer and die rapidly as a consequence.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, elderly, mortality, stage, survival | 11 Comments »
A new study just published in the Journal of General Internal Medicine makes a strong case for the importance of individualized application of specific treatments to older men diagnosed with prostate cancer — something which you would think ought to be evident to the majority of clinicians, but apparently wasn’t
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Co-morbidity, Diagnosis, Management, mortality, prognosis, risk | Leave a Comment »
Between 1981 and 1983 researchers collected and stored blood samples from 4,500 men in Copenhagen, Denmark, as part of the Copenhagen City Heart Study. These blood samples had been carefully stored — and otherwise unused — for nearly 30 years. In 2010, a new research team decided to measure the PSA levels in these blood [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, long-term, mortality, PSA, risk, screening | 5 Comments »
There is an interesting article on Kaiser Health News today discussing the risks associated with “over-testing” of elderly and sometimes very infirm people who are at relatively low risk for specific chronic diseases, including prostate cancer.
Filed under: Diagnosis, Risk | Tagged: aging, life expectancy, mortality, over-testing, risk, screening | 7 Comments »
The association of depression with a diagnosis of and subsequent treatment for prostate cancer is well appreciated, but the prevalence of that depression and the burden it places on men with prostate cancer over time has been less well documented.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: depression, mortality, outcome, risk | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site